Recent updates to the iPLEDGE program and a failed attempt to update the website has left prescribers, patients and pharmacies without the access to the drug Isotretinoin. The iPLEDGE program was implemented in 2005 with the goal of preventing fetal exposure to the drug Isotretinoin and allowing access to a centralized system for prescribers, pharmacies and patients to manage patient risk, regardless of which Isotretinoin product they are prescribed. This issue is not limited to patients of Valley Dermatology Associates, it is impacting all offices authorized to prescribe this medication.
Today, 12/16/21, the USDA has called an emergency meeting to discuss the failed rollout of the updated iPLEDGE system and how corrections can be made quickly. In an effort to provide timely information and updates on situation and potential correction of the problems, the FDA will post all related updates as they arise. Information can be found at https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems and www.ipledgeprogram.com
At Valley Dermatology Associates we clearly understand how inconvenient and disruptive a delay in treatment can be and we echo your frustrations with this iPLEDGE update. We encourage you to use the links provided as you look for information and updates. Our staff is poised to act as soon as a clear plan for all prescribers is presented so please hold your calls. Repeated calls to our office about iPLEDGE and your prescription will create a backlog that will delay any corrections once a solution is available.